Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07340268
Recruiting Not applicable

The Effects of Transcranial Current Stimulation on Insomnia

NCT07340268 · tracked via the Priya Life Science China tracker
Sponsor
Zan Wang
Phase
Not applicable
Started
2026-01-18
Last updated
2026-02-04

Condition(s) studied

Insomnia, Psychophysiological

Investigational drug(s) / intervention(s)

transcranial current stimulationSham stimulation

transcranial current stimulation: consecutive daily 20-min, 1.1-mA sessions

Sham stimulation: only wore the device and had no stimulation

Study summary

Effect of transcranial current stimulation on insomnia disorder

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Clinical diagnosis of insomnia disorder * Cooperate to complete the questionnaire surveys Exclusion Criteria: * Presence of mental disorders * Current use of central nervous system stimulants * Use of analgesics,sedatives or hypnotic medications, theophylline preparations, steroid medications * Alcohol abuse or regular alcohol consumption * Diagnosis of other sleep disorders, including obstructive sleep apnea, rapid eye movement sleep behavior disorder, or restless legs syndrome * Sleep disorders secondary to organic diseases, such as epilepsy, diabetes, or renal failure * Shift work or irregular work schedules that disrupt normal circadian rhythms * Use of medications affecting central nervous system function within the past one month * Recent sleep-related confounding behaviors within the past two weeks, including staying up late, alcohol consumption, or smoking * Presence of organic brain lesions on head MRI and contraindications to MRI examination

Primary outcome measure(s)

  • Change in global blood-oxygen-level-dependent (gBOLD) signal amplitude — 2 weeks and 3 months
    The amplitude of the global blood-oxygen-level-dependent (gBOLD) signal was derived from resting-state functional MRI and reflects the overall magnitude of spontaneous brain activity. Unit of Measure: Z-score
  • Change in resting-state functional connectivity strength — 2 weeks and 3 months
    Resting-state functional connectivity strength was calculated as the correlation coefficient between predefined brain regions based on functional magnetic resonance imaging data.
  • Change in amplitude of low-frequency fluctuations — 2 weeks and 3 months
    Amplitude of low-frequency fluctuations was calculated from resting-state fMRI to quantify spontaneous neural activity.
  • Change in regional homogeneity — 2 weeks and 3 months
    Regional homogeneity was used to assess the synchronization of local spontaneous brain activity
  • Change in phase difference of dynamic cerebral autoregulation — 2 weeks and 3 months
    Dynamic cerebral autoregulation was assessed using the phase difference between cerebral blood flow velocity and arterial blood pressure fluctuations. Larger phase differences indicate better autoregulatory function.
  • Change in gain of dynamic cerebral autoregulation — 2 weeks and 3 months
    Gain represents the magnitude of cerebral blood flow velocity changes in response to blood pressure fluctuations, with lower gain values indicating more effective autoregulation.

Trial sites (2)

FacilityCityRegionStatus
the First Hospital of Jilin University Ch’ang-ch’un Jilin Completed
the First Hospital of Jilin University Ch’ang-ch’un Jilin Recruiting

More Zan Wang trials in China

Clinical Efficacy and Health Economic Evaluation of an Intelligent Diagnostic and Treatment Model Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07340268 on ClinicalTrials.gov ↗ ← All trials in China